Image For Activity Cover
The Lead Episode 28: Results of the FRAIL-AF Randomized Controlled Trial
Description

William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by guests Erik Andrews, MD, MPH, and Christian Thomas Ruff, MD, MPH, of Brigham and Women's Hospital to discuss Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. In the FRAIL-AF clinical trial, there were more bleeding events when elderly patients were switched from warfarin to rivaroxaban, apixaban, edoxaban, or dabigatran.

Learning Objectives
  • To discuss the outcomes of the research paper, "Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial."
Article Authors and Podcast Contributors
Article Authors
Linda P.T. Joosten, MD, Sander van Doorn, MD, PhD, Peter M. van de Ven, PhD, Bart T.G. Köhlen, Melchior C. Nierman, MD, PhD, Huiberdina L. Koek, MD, PhD, Martin E.W. Hemels, MD, PhD, Menno V. Huisman, MD, PhD, Marieke Kruip, MD,PhD, Laura M. Faber, MD, PhD, Nynke M. Wiersma, MD, Wim F., Rob Fijnheer, MD, PhD, Henk J. Adriaansen, MD, PhD, Kit C. Roes, PhD, Arno W. Hoes, MD, PhD, Frans H. Rutten MD, PhD, Geert-Jan Geersing MD, PhD

Podcast Contributors
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital
Erik Andrews, MD, MPH, of Brigham and Women’s Hospital
Christian Thomas Ruff, MD, MPH, of Brigham and Women's Hospital
Disclosures

 

All relevant financial relationships have been mitigated.

Host Disclosure(s):
W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic

Contributor Disclosure(s):
E. Andrews: No relevant financial relationships with ineligible companies to disclose. 
C. Ruff: Honoraria/Speaking/Consulting Fee: Bayer Healthcare Pharmaceuticals, Janssen Pharmaceuticals, Daiichi, Boehringer Ingelheim, Bristol-Myers Squibb, Portola Pharmaceuticals; Research (Contracted Grants for PIs Named Investigators Only): Daiichi, MedImmune



Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose. 
S. Sailor: No relevant financial relationships with ineligible companies to disclose.
Summary
Availability: On-Demand
Cost: FREE
Credit Offered:
No Credit Offered
Recommended
  Heart Rhythm Society
1325 G Street NW, Suite 500
Washington, DC 20005
P: 202-464-3400 F: 202-464-3401
E: questions@heartrhythm365.org
© Heart Rhythm Society
Privacy Policy | Cookie Declaration | Linking Policy | Patient Education Disclaimer | State Nonprofit Disclosures | FAQ
 
Android App Download IOS App Download Powered By